IRIS
TIRIBELLI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.568
AS - Asia 5.781
EU - Europa 3.701
SA - Sud America 1.180
AF - Africa 126
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 10
Totale 23.407
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.346
SG - Singapore 2.664
CN - Cina 1.216
BR - Brasile 944
UA - Ucraina 886
HK - Hong Kong 586
VN - Vietnam 525
DE - Germania 521
FR - Francia 417
FI - Finlandia 395
IT - Italia 371
RU - Federazione Russa 291
SE - Svezia 183
IE - Irlanda 176
IN - India 161
CA - Canada 154
TR - Turchia 142
GB - Regno Unito 131
AR - Argentina 102
NL - Olanda 100
KR - Corea 71
JP - Giappone 57
BD - Bangladesh 56
IQ - Iraq 50
PL - Polonia 49
ID - Indonesia 47
AT - Austria 38
AU - Australia 38
ES - Italia 36
PK - Pakistan 36
ZA - Sudafrica 33
MX - Messico 32
CO - Colombia 30
EC - Ecuador 30
MA - Marocco 24
IR - Iran 23
UZ - Uzbekistan 18
CL - Cile 17
SA - Arabia Saudita 17
VE - Venezuela 17
BE - Belgio 16
EG - Egitto 16
CZ - Repubblica Ceca 15
GR - Grecia 14
KE - Kenya 14
PY - Paraguay 14
JO - Giordania 13
PE - Perù 12
AE - Emirati Arabi Uniti 10
CH - Svizzera 10
PH - Filippine 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
TG - Togo 8
UY - Uruguay 8
EU - Europa 7
LB - Libano 7
LT - Lituania 7
OM - Oman 7
AL - Albania 6
CR - Costa Rica 6
ET - Etiopia 6
PA - Panama 6
BG - Bulgaria 5
BH - Bahrain 5
BO - Bolivia 5
HU - Ungheria 5
JM - Giamaica 5
KG - Kirghizistan 5
LY - Libia 5
NP - Nepal 5
TH - Thailandia 5
AO - Angola 4
HN - Honduras 4
IL - Israele 4
MY - Malesia 4
RO - Romania 4
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
HR - Croazia 3
LU - Lussemburgo 3
LV - Lettonia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
TN - Tunisia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BB - Barbados 2
DZ - Algeria 2
GA - Gabon 2
GE - Georgia 2
MD - Moldavia 2
NG - Nigeria 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
Totale 23.380
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.487
Fairfield 1.407
Singapore 1.034
Ashburn 951
Houston 916
Ann Arbor 880
Beijing 601
Seattle 581
Hong Kong 579
Jacksonville 579
Chandler 551
Wilmington 495
Cambridge 474
Dearborn 395
San Jose 326
Boardman 240
Lauterbourg 193
Princeton 181
Dublin 173
Los Angeles 155
Dallas 149
Ho Chi Minh City 149
Council Bluffs 113
Dong Ket 110
Buffalo 107
Udine 106
Helsinki 104
Izmir 99
Hanoi 88
Munich 85
San Diego 83
Hefei 78
New York 72
São Paulo 72
Seoul 65
Tokyo 57
Amsterdam 55
Ogden 54
Redondo Beach 53
The Dalles 50
Des Moines 46
Warsaw 44
Frankfurt am Main 39
Calgary 38
Norwalk 37
Nanjing 35
Phoenix 35
Trieste 35
Turku 35
Orem 34
Santa Clara 34
Ottawa 32
Melbourne 29
Nuremberg 27
Chennai 26
Mumbai 26
Pittsburgh 26
Chevy Chase 25
Rio de Janeiro 25
Montreal 24
Stanford 24
Salvador 23
Guangzhou 22
Kunming 21
Toronto 21
Brooklyn 20
Hangzhou 20
Lutz 20
Belo Horizonte 19
Porto Alegre 19
Vienna 19
Boston 18
Stockholm 18
Tashkent 18
Baghdad 17
Milan 17
Philadelphia 17
Cardiff 16
Istanbul 16
Johannesburg 16
London 16
Paris 16
Redmond 16
Atlanta 15
Vancouver 15
Brussels 14
Chicago 14
Da Nang 14
Lille 14
New Delhi 14
Washington 14
Denver 13
Duino-Aurisina 13
Haiphong 13
Lappeenranta 13
San Francisco 13
Santa Maria 13
Shanghai 13
Amman 12
Hyderabad 12
Totale 15.257
Salva come PNG Salva come JPEG
Nome #
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 676
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 222
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology 217
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 204
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. 200
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 198
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 197
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 196
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 189
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 183
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 180
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 177
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 177
Histone post-translational modifications associated to BAALC expression in leukemic cells. 173
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 173
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 173
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 172
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 172
All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines 170
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 170
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 166
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 164
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 160
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors 159
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 157
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 157
Erratum: Functional regulation of the Apurinic/apyrimidinic endonuclease APE1 by Nucleophosmin (NPM1): Impact on tumor biology 155
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 151
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 151
Unexpected phenotype of a typical NPM1 mutant 149
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 149
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 147
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 147
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 147
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 145
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 145
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 144
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 144
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. 144
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 143
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. 143
ABCB1 (PGP) and ABCG (BCRP) proteins are independent prognostic factors for complete remissione and relapse risk, respectively in normal karyotype adult de novo acute myeloid leukemia. 142
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 142
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 141
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 141
Evaluation of residual CD34+ Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy 140
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 139
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 139
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 139
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. 138
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. 138
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 138
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 138
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 138
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 136
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia 136
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data 135
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia 135
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 135
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 134
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 133
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 133
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 133
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients 132
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. 132
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 131
Prognostic factors anad expression of multidrug-resistance related proteins in 36 patients with acute promyelocytic leukemia. 130
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 130
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia 129
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 129
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. 128
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib 128
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 127
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 127
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? 126
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 125
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 125
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 124
How could patient reported outcomes improve patient management in chronic myeloid leukemia? 124
Epstein-Barr virus (EBV) reactivation in a patient treated with ATG for severe aplastic anemia 123
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 123
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 122
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicinee—Results from the Italian ‘Back to Life’ project 122
A SIMPLE PROGNOSTIC SCORING SYSTEM FOR NEWLY DIAGNOSED ACUTE LEUKAEMIA PATIENTS WITH NORMAL KARYOTYPE: A RETROSPECTIVE ANALYSIS ON 420 CASES 121
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 121
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 120
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 120
The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. 120
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 119
GVHD and cyclosporien levels in blood in different moments after allogeneic bone marrow transplantation: an open question? 118
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 118
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase 117
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 117
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 117
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 117
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. 116
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. 116
The efficacy of imatinib mesylate in patients with the FIP1L1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study 115
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. 115
The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. 115
Totale 14.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.760
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021525 0 0 0 0 0 0 0 0 0 85 232 208
2021/20221.348 64 145 51 65 23 66 78 60 16 226 325 229
2022/20231.338 199 80 8 156 136 391 6 108 170 24 43 17
2023/2024474 65 48 11 24 52 38 8 49 76 38 24 41
2024/20253.547 79 251 113 141 125 141 235 223 361 331 542 1.005
2025/20266.888 608 773 646 800 1.036 622 883 292 627 601 0 0
Totale 23.920